Stocks · News reference

Reported Sunday, BridgeBio’s Encaleret Raises Bone Turnover, With 100% Of Phase 3 CALIBRATE Participants Reporting Improvement In At Least One ADH1 Symptom Versus 46% On Standard Of Care

Oct 12, 2026, 7:04 AMBenzinga Newsdesk

- Encaleret administration increased bone turnover, based on its action to recover endogenous PTH secretion in patients with ADH1- 100% of participants who received encaleret reported improvements in at least one ADH1

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BBIO

Source: benzinga
Observed: Oct 12, 2026, 7:04 AM
Checked: Oct 12, 2026, 7:04 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 12, 2026, 6:56 AMBenzinga Newsdesk
Reported Sunday, BridgeBio Presents Acoramidis Data At HFSA 2026 Showing 18% Lower Composite Risk Versus Tafamidis In Real-World Study Of 2,684 ATTR-CM Patients And Mortality Rising After Cardiovascular Hospitalizations
- In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U.S. electronic health record database, acoramidis was associated with a statistically
BBIO
BenzingaOct 7, 2026, 1:33 PMBenzinga Newsdesk
Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156
Barclays analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $157 to $156.
BBIO
BenzingaOct 6, 2026, 8:03 PMBenzinga Newsdesk
BridgeBio Announces Presentation Of Attruby Amyloid Heart Disease Data At HFSA October 9-12, Including Real-World Comparison vs. Tafamidis
BBIO

Reported Sunday, BridgeBio’s Encaleret Raises Bone Turnover, With 100% Of Phase 3 CALIBRATE Participants Reporting Improvement In At Least One ADH1 Symptom Versus 46% On Standard Of Care

Connected Markets

Related Headlines

Reported Sunday, BridgeBio Presents Acoramidis Data At HFSA 2026 Showing 18% Lower Composite Risk Versus Tafamidis In Real-World Study Of 2,684 ATTR-CM Patients And Mortality Rising After Cardiovascular Hospitalizations

Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156

BridgeBio Announces Presentation Of Attruby Amyloid Heart Disease Data At HFSA October 9-12, Including Real-World Comparison vs. Tafamidis